Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 4,600 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $85.42, for a total transaction of $392,932.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total value of $631,738.00.

Kymera Therapeutics Stock Up 0.6%

Shares of NASDAQ KYMR opened at $85.40 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00. The business has a fifty day simple moving average of $81.26 and a two-hundred day simple moving average of $71.73. The firm has a market cap of $6.97 billion, a PE ratio of -23.21 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the company earned ($0.88) earnings per share. The firm’s revenue was down 60.8% on a year-over-year basis. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently modified their holdings of KYMR. Federated Hermes Inc. bought a new stake in Kymera Therapeutics during the 3rd quarter worth approximately $31,622,000. Hudson Bay Capital Management LP lifted its stake in Kymera Therapeutics by 362.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after purchasing an additional 18,134 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Kymera Therapeutics by 77.2% during the second quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after buying an additional 10,052 shares during the last quarter. Candriam S.C.A. boosted its position in shares of Kymera Therapeutics by 24.4% during the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after acquiring an additional 37,536 shares during the last quarter. Finally, Frontier Capital Management Co. LLC increased its holdings in shares of Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently commented on KYMR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Piper Sandler upped their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Stifel Nicolaus set a $114.00 price target on shares of Kymera Therapeutics in a report on Monday, December 8th. Wells Fargo & Company raised their price objective on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.